Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Innate Pharma S.A. ADR (NQ: IPHA ) 1.845 UNCHANGED Streaming Delayed Price Updated: 1:28 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Innate Pharma S.A. ADR < Previous 1 2 3 4 5 6 7 8 Next > 12 Health Care Stocks Moving In Monday's Pre-Market Session April 01, 2024 Via Benzinga Earnings Scheduled For March 21, 2024 March 21, 2024 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Via Benzinga Innate Pharma Reports Full Year 2023 Financial Results and Business Update March 21, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Its Participation to Upcoming Investor Conference March 19, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results March 14, 2024 From Innate Pharma SA Via Business Wire 12 Health Care Stocks Moving In Monday's After-Market Session March 11, 2024 Via Benzinga Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024 March 06, 2024 From Innate Pharma SA Via Business Wire Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma March 06, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Its Participation to Upcoming Investor Conference February 21, 2024 From Innate Pharma SA Via Business Wire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 06, 2024 Via Benzinga Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024 January 12, 2024 From Innate Pharma S.A. Via Business Wire Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program January 04, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board January 04, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi December 19, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Announces Leadership Change December 18, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023 December 11, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023 December 10, 2023 From Innate Pharma SA Via Business Wire Innate Pharma to Host Virtual KOL Event on Lacutamab November 27, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update November 14, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update November 07, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023 November 03, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Announces Its Participation to Upcoming Investor Conferences October 27, 2023 From Innate Pharma SA Via Business Wire Innate Pharma 2024 Financial Calendar October 19, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Announces Abstracts Selected for ESMO Congress 2023 October 16, 2023 From Innate Pharma SA Via Business Wire Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023 October 09, 2023 From Innate Pharma SA Via Business Wire 12 Health Care Stocks Moving In Thursday's Pre-Market Session October 05, 2023 Via Benzinga Regulatory Hurdle For Innate Pharma's Blood Cancer Studies October 05, 2023 The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201... Via Benzinga Exposures Product Safety Innate Pharma Provides Update on Lacutamab Clinical Program October 05, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023 September 22, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Reports First Half 2023 Financial Results and Business Update September 14, 2023 From Innate Pharma SA Via Business Wire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
